Privia Health Group (NASDAQ:PRVA) Director Sells $25,384.32 in Stock

Privia Health Group, Inc. (NASDAQ:PRVA) Director Matthew Shawn Morris sold 1,017 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $24.96, for a total transaction of $25,384.32. Following the sale, the director directly owned 68,188 shares in the company, valued at $1,701,972.48. The trade was a 1.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Matthew Shawn Morris also recently made the following trade(s):

• On Friday, May 1st, Matthew Shawn Morris sold 17,096 shares of Privia Health Group stock. The stock was sold at an average price of $24.99, for a total transaction of $427,229.04.
• On Thursday, February 26th, Matthew Shawn Morris sold 7,788 shares of Privia Health Group stock. The stock was sold at an average price of $24.99, for a total transaction of $194,622.12.
• On Friday, February 27th, Matthew Shawn Morris sold 16,550 shares of Privia Health Group stock. The stock was sold at an average price of $25.00, for a total transaction of $413,750.00.

Privia Health Group Price Performance

NASDAQ:PRVA traded up $0.05 during mid-day trading on Tuesday, hitting $24.29. 980,019 shares of the company’s stock were exchanged, compared to its average volume of 838,913. Privia Health Group, Inc. has a one year low of $18.77 and a one year high of $26.51. The business has a fifty day moving average price of $22.59 and a 200 day moving average price of $23.37. The company has a market cap of $3.05 billion, a PE ratio of 142.88, a P/E/G ratio of 1.55 and a beta of 0.96.

Privia Health Group (NASDAQ:PRVA) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.04 by $0.21. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. The business had revenue of $541.17 million for the quarter, compared to analyst estimates of $516.61 million. During the same quarter in the previous year, the firm posted $0.21 earnings per share. Privia Health Group’s quarterly revenue was up 17.4% on a year-over-year basis. On average, equities analysts forecast that Privia Health Group, Inc. will post 0.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in PRVA. Bayban purchased a new position in shares of Privia Health Group during the fourth quarter valued at approximately $26,000. Hantz Financial Services Inc. raised its holdings in shares of Privia Health Group by 456.2% during the fourth quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock valued at $27,000 after purchasing an additional 926 shares during the last quarter. Global Retirement Partners LLC raised its holdings in shares of Privia Health Group by 579.8% during the fourth quarter. Global Retirement Partners LLC now owns 1,584 shares of the company’s stock valued at $38,000 after purchasing an additional 1,351 shares during the last quarter. Canada Pension Plan Investment Board raised its holdings in shares of Privia Health Group by 48.0% during the second quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock valued at $85,000 after purchasing an additional 1,200 shares during the last quarter. Finally, Kestra Advisory Services LLC purchased a new position in shares of Privia Health Group during the fourth quarter valued at approximately $93,000. 94.48% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on PRVA. Jefferies Financial Group reaffirmed a “buy” rating and issued a $32.00 target price on shares of Privia Health Group in a report on Thursday, February 26th. Wolfe Research set a $31.00 target price on shares of Privia Health Group in a report on Tuesday, January 6th. Citigroup decreased their target price on shares of Privia Health Group from $34.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, March 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Privia Health Group in a report on Friday, March 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $36.00 target price on shares of Privia Health Group in a report on Thursday, February 26th. Eleven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.31.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.